How to Get Rezlidhia (olutasidenib) Covered by UnitedHealthcare in Pennsylvania: Prior Authorization, Appeals, and Renewal Guide
Answer Box: Getting Rezlidhia (olutasidenib) covered by UnitedHealthcare in Pennsylvania requires prior authorization with IDH1 mutation testing, documented AML diagnosis, and prior therapy history. If denied, you have 180 days for internal appeals, then 4 months for Pennsylvania's external review (50% overturn rate). Start by having your oncologist